Focus.
Shouval
Daniel
D
Hadassah Hebrew University Hospital, Liver Unit, Division of Medicine, PO Box 12000, Jerusalem 91120, Israel. shouval@cc.huji.ac.il
D000418:Albumins / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001086:Arabinofuranosyluracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000150:complications*; D002779:Cholestasis / Q000150:complications*; D015314:Dialysis Solutions / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology*; D006509:Hepatitis B / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D009135:Muscular Diseases / Q000139:chemically induced*; D011537:Pruritus / Q000628:therapy*; D006435:Renal Dialysis / Q000379:methods; D012307:Risk Factors
D000418:Albumins; D000998:Antiviral Agents; D015314:Dialysis Solutions; D001086:Arabinofuranosyluracil; C034935:clevudine